Imunon
IMNN
Market cap $10.8M

0.7480 USD

+0.0013

0.17%

At close Nov 14, 4:00 PM EST

After hours

0.7251

-0.0229

3.06%

1 day

0.17%

5 days

-8.37%

1 month

-27.38%

3 months

-21.79%

6 months

-44.59%

Year to date

9.98%

1 year

-21.26%

5 years

-96.41%

10 years

-99.86%

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,759 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

0.38% more ownership

Funds ownership: 3.6% [Q1] → 3.98% (+0.38%) [Q2]

6% less funds holding

Funds holding: 18 [Q1] → 17 (-1) [Q2]

19% less capital invested

Capital invested by funds: $545K [Q1] → $444K (-$101K) [Q2]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

1,504%

upside

Avg. target

$23

2,921%

upside

High target

$29

3,777%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar 36% 1-year accuracy 33 / 91 met price target	1,504%upside $12	Buy Maintained	11 Nov 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 33 / 84 met price target	3,777%upside $29	Buy Maintained	7 Nov 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 33 / 84 met price target	3,777%upside $29	Buy Maintained	31 Oct 2024
EF Hutton Jason Kolbert 39% 1-year accuracy 33 / 84 met price target	3,777%upside $29	Buy Initiated	23 Sept 2024
HC Wainwright & Co. Emily Bodnar 36% 1-year accuracy 33 / 91 met price target	1,772%upside $14	Buy Reiterated	15 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about IMNN published over the past 30 days

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

Imunon, Inc. (NASDAQ:IMNN ) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Conference Call Participants David Bautz - Zacks Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Hello everyone. Good morning.

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is expected to begin in Q1 2025 LAWRENCEVILLE, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of advanced ovarian cancer, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held November 6-10, 2024, in Houston, Texas and virtually.

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company's common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total of 50,000 shares of common stock to Susan Eylward, hired by Imunon as General Counsel and Secretary effective October 7, 2024 (collectively, the “Inducement Option Grants”). The Inducement Option Grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and were made on October 7, 2024, as a material inducement to each employee's entry into employment with the Company.

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMUNON to Host R&D Day on September 18th

R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark their calendars for its R&D Day event to be held at the Harvard Club in New York City on September 18th from 10:00 a.m.

IMUNON to Host R&D Day on September 18th

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Imunon, Inc. (NASDAQ:IMNN ) Q2 2024 Results Conference Call August 14, 2024 11:00 AM ET Company Participants Kim Golodetz - IR Michael Tardugno - Executive Chairman Stacy Lindborg - President and CEO David Gaiero - Interim CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets David Bautz - Zacks James Molloy - Alliance Global Partners Operator Good morning, everyone.

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

See News Rankings

Charts implemented using Lightweight Charts™